Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1983-11-23
1988-05-24
Wiseman, Thomas G.
Drug, bio-affecting and body treating compositions
Lymphokine
435 7, 435 68, 435 70, 435 29, 514 2, 514 6, 424 88, 530352, 530828, 530830, 436548, C12Q 100, C12P 2100, C12P 2102, A61K 3900
Patent
active
047465395
ABSTRACT:
It has previously been shown that the serum from patients suffering from a wide range of cancers contains a cancer marker protein having the ability to release RNA from cell nuclei. This cancer marker protein is purified by taking the protein fraction precipitating between 30% and 50% saturated aqueous ammonium sulfate solution, dialyzing a solution of the protein fraction against TMK buffer, chromatographing the dialyzed protein on a molecular sieve and isolating the fraction having a molecular weight of about 60,000; and removing albumin. Injection of the purified protein into rabbits, preparation of serum from blood of the rabbits and absorption of the sera with normal plasma fraction produces at antibody specific to the cancer marker protein and therefore useful in a radioimmunoassay or ELISA test for a wide variety of cancers. Monoclonal antibody preparations to the protein may be prepared by injecting the purified protein into mice, harvesting the spleen and lymph node cells, fusing these cells with mouse myeloma cells and using the resultant hybridoma cells to produce the monoclonal antibody.
REFERENCES:
patent: 4126671 (1978-11-01), House et al.
patent: 4160019 (1979-07-01), Bjorklund
patent: 4264589 (1981-04-01), Felts et al.
patent: 4270924 (1981-06-01), Crooke et al.
patent: 4288540 (1981-09-01), Turcotte
patent: 4317877 (1982-03-01), Balis et al.
Durban et al, Cancer Research, vol. 41, pp. 535-545, Feb. 1981, "Purification and Characterization of Nuclear DNA-Binary Phosphoprotein in Fetal and Tumor Tissues".
Schumm et al, J. Nat. Cancer Inst.vol. 54, pp. 123-128, 1975, "Modification of Nuclear Restriction in Vitro by Plasma from Tumor-Bearing Animals".
Tamura et al, Cell, vol. 34, pp. 587-596, Sep. 1983, "Antibodies Against Synthetic Peptides as a Tool for Functional Analysis of the Transforming Protein, p. 60".
Leppard et al, EMBO Journal, vol. 2(9), Sep. 1983, pp. 1457-1464, "Monoclonal Antibodies Displaying a Novel Species Specificity for the Primatic Transformation Protein p. 53".
Walaszek et al., Biol. Abstracts, No. 7658, Oct. 1983, "An Oncofetal 60-Kilodlalton Protein on the Plasma of Tumor Bearing and Carcinogen Treated Mice".
Davis et al, "Differences in Nucleolar Antigens of Rat Liver and Novikoff Hepatoma Ascites Cells" in Cancer Research 38, 1900-1915, Jul. 1978.
Farhad Marashi et al., "Purification and Partial Characterization of Nucleolar Antigen-1 of the Novikoff Hepatoma" in Cancer Research 39, 59-66, Jan. 1979.
Frances M. Davis et al, "Nucleolar Antigen Found in Several Human Tumors But Not in the Nontumor Tissues Studied" in Proc. Natl. Acad. Sci., USA, vol. 766, No. 2, pp. 892-896, Feb. 1979.
Harris Busch et al., "A Nucleolar Antigen Found in a Broad Range of Human Malignant Tumor Specimens" in Cancer Research 39, 3024-3030, Aug. 1979.
Jo Hilgers et al., "Detection of Avian and Mammalian Oncogenic RNA Viruses (Oncornaviruses) by Immunofluorescence" in Cancer Research 32, 98-106, Jan. 1972.
Rose K. Busch et al. "Rabbit Antibodies to Nucleoli of Novikoff Hepatoma and Normal Liver of the Rat" in Cancer Research 34, 2362-2367, Sep. 1974.
Karel Smetana et al., "Nucleolar Immunofluorescence in Human Hematological Malignancies" in Life Sciences, vol. 25, pp. 227-234.
Bio-Rad Laboratories, price list G, Feb. 1981, front sheet and pp. 40, 43 and index page.
Nature New Biology, 245, 201-203 (1973).
Biochem. J., 139, 191-196 (1974).
Schumm et al, Biochem. Biophys. Res. Comm. 48:1259 (1972).
Cancer Res., 33:1821 (1973).
Biochem. Biophys. Res. Comm., 58:354 (1974).
Biochem. J., 154:379 (1976).
Nature, 256:508 (1975).
Der et al., "A Tumor-Specific Membrane Phosphoprotein Marker in Human Cell Hybrids", Cell, vol. 26, 429-438, Nov. 1981.
Schumm et al., "Absence of the Cancer-Associated Factor with a Molecular Weight of 60,000 from the Plasma of Patients with a Spectrum of Nonneoplastic Conditions," Cancer Research 44, 401-406, Jan. 1984.
Hanausek-Walaszek, et al., "Characterizatin of a 60,00-Dalton Circulated Oncofetal Protein from the Plasma of Tumor-Bearing Rats", Cancer Investigation2(6), 433-441 (1984).
French et al., "Nucleocytoplasmic Release of Repetitive DNA Transcripts in Carcinogenesis Correlates with a 60 Kilodalton Cytoplasmic Protein", Cancer Letters, 23, 45-52 (1984).
Walaszek, et al., "Inhibition of 7,12-Dimethylbenzanthracene-Induced Rat Mammary Tumorigenesis by 2,5-Di-)-Acetyl-D-Glucaro-1,4:6,3-Dilactin, an in vivo-Glucoronidase Inhibitor", Carcinogenesis, 5(6), 767-772, (1984).
Hanausek-Walaszek et al., "Immunological Indentity of a 60 KD Oncofetal Protein Induced in Rats by Chemical Carcinogens and Released by Transformed Cells", Biochem. Biophys. Res. Comm. 127(3), 777-785, Mar. 29, 1985.
Walaszek et al., "An Oncofetal 60-kilodalton Protein in the Plasma of Tumor-Bearing and Carcinogen-Treated Rats", Cancer Letters, 20, 277-282 (1983).
Schumm et al., "Putative Transformation-Dependent Proteins in the Blood Plasma of Tumor-Bearing Rats and Cancer Patients", Cancer Research, 42, 4964-4969, Dec. 1982.
Schumm et al., "Apparent Transformed Cell-Dependent Proteins in Blood Plasma", Abstract No. 313 of American Association of Cancer Research (1981).
Schumm et al., "Changes in Nuclear RNA Transport Incident to Carcinogenesis", Eur. J. Cancer, 13, 139-147 (1977).
Hanausek-Walaszek Margaret
Schumm Dorothy E.
Webb Thomas E.
Teskin Robin Lyn
The Ohio State University Research Foundation
Wiseman Thomas G.
LandOfFree
Purification of cancer-associated protein and preparation of ant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purification of cancer-associated protein and preparation of ant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purification of cancer-associated protein and preparation of ant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1057635